List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6971364/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature, 2008, 453, 1117-1121.	13.7	348
2	Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen. Diabetes, 2014, 63, 2120-2131.	0.3	298
3	Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Frontiers in Endocrinology, 2013, 4, 7.	1.5	186
4	Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical Science, 2013, 124, 153-164.	1.8	182
5	Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clinical and Experimental Nephrology, 2013, 17, 488-497.	0.7	145
6	Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11109-11114.	3.3	142
7	The biology of preeclampsia. Kidney International, 2009, 76, 831-837.	2.6	135
8	Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight, 2020, 5, .	2.3	131
9	Interactions of DPP-4 and integrin \hat{l}^21 influences endothelial-to-mesenchymal transition. Kidney International, 2015, 88, 479-489.	2.6	127
10	Biology of Obesity: Lessons from Animal Models of Obesity. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	126
11	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp> â€ <scp>T2D</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 1610-1619.	2.2	119
12	SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis. Cell Death and Disease, 2018, 9, 997.	2.7	117
13	Integrin \hat{I}^21 -mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Developmental Biology, 2008, 313, 584-593.	0.9	115
14	MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT. BioMed Research International, 2013, 2013, 1-10.	0.9	104
15	Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a highâ€fat diet. Journal of Diabetes Investigation, 2018, 9, 1025-1032.	1.1	88
16	Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial–Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis. Cancer Research, 2019, 79, 735-746.	0.4	86
17	microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney. Frontiers in Pharmacology, 2019, 10, 904.	1.6	84
18	N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits TGF-β–Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2003, 14, 863-872.	3.0	80

#	Article	IF	CITATIONS
19	Preeclampsia. American Journal of Pathology, 2010, 176, 710-720.	1.9	79
20	Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. Nature Communications, 2021, 12, 2368.	5.8	79
21	A very-low-protein diet ameliorates advanced diabetic nephropathy through autophagy induction by suppression of the mTORC1 pathway in Wistar fatty rats, an animal model of type 2 diabetes and obesity. Diabetologia, 2016, 59, 1307-1317.	2.9	75
22	The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clinical Science, 2018, 132, 489-507.	1.8	75
23	Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends in Endocrinology and Metabolism, 2010, 21, 529-536.	3.1	73
24	N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition. BioMed Research International, 2014, 2014, 1-12.	0.9	73
25	N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Prevents Renal Insufficiency and Mesangial Matrix Expansion in Diabetic db/db Mice. Diabetes, 2005, 54, 838-845.	0.3	66
26	Endothelial autophagy deficiency induces IL6 - dependent endothelial mesenchymal transition and organ fibrosis. Autophagy, 2020, 16, 1905-1914.	4.3	65
27	FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway. Cell Death and Disease, 2017, 8, e2965-e2965.	2.7	61
28	Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis. Scientific Reports, 2016, 6, 29884.	1.6	60
29	N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Ameliorates the Progression of Renal Dysfunction and Fibrosis in WKY Rats with Established Anti–Glomerular Basement Membrane Nephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 674-685.	3.0	55
30	Endothelial FGFR1 (Fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice. Hypertension, 2020, 76, 1935-1944.	1.3	55
31	Lipid mediators in diabetic nephropathy. Fibrogenesis and Tissue Repair, 2014, 7, 12.	3.4	54
32	Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs. Genes, 2020, 11, 211.	1.0	54
33	The Role of Ubiquitination and Sumoylation in Diabetic Nephropathy. BioMed Research International, 2014, 2014, 1-11.	0.9	51
34	Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis and Tissue Repair, 2016, 9, 1.	3.4	50
35	Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys. IScience, 2021, 24, 102390.	1.9	50
36	Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clinical and Experimental Nephrology, 2015, 19, 1098-1106.	0.7	49

#	Article	IF	CITATIONS
37	The PKM2 activator TEPPâ€46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIFâ€1α accumulation. Journal of Diabetes Investigation, 2021, 12, 697-709.	1.1	44
38	Diabetic angiopathy and angiogenic defects. Fibrogenesis and Tissue Repair, 2012, 5, 13.	3.4	43
39	Clinical therapeutic strategies for early stage of diabetic kidney disease. World Journal of Diabetes, 2014, 5, 342.	1.3	42
40	Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. Journal of Clinical Investigation, 2018, 128, 5008-5017.	3.9	42
41	Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats. Redox Report, 2018, 23, 153-159.	1.4	42
42	Metabolic reprogramming by <i>N</i> â€acetylâ€serylâ€aspartylâ€lysylâ€proline protects against diabetic kidney disease. British Journal of Pharmacology, 2020, 177, 3691-3711.	2.7	42
43	Pathophysiology of the aging kidney and therapeutic interventions. Hypertension Research, 2012, 35, 1121-1128.	1.5	41
44	Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochemical and Biophysical Research Communications, 2016, 471, 184-190.	1.0	38
45	The Effect of Piceatannol from Passion Fruit (Passiflora edulis) Seeds on Metabolic Health in Humans. Nutrients, 2017, 9, 1142.	1.7	38
46	Loss of β1â€integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB Journal, 2013, 27, 1950-1961.	0.2	37
47	Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. BioMed Research International, 2016, 2016, 1-11.	0.9	36
48	The biological consequence of obesity on the kidney. Nephrology Dialysis Transplantation, 2013, 28, iv1-iv7.	0.4	33
49	Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice. Scientific Reports, 2017, 7, 7927.	1.6	30
50	Ketogenic essential amino acids replacement diet ameliorated hepatosteatosis with altering autophagy-associated molecules. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1605-1612.	1.8	28
51	Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II. Hypertension, 2017, 69, 1156-1164.	1.3	28
52	N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Frontiers in Pharmacology, 2014, 5, 70.	1.6	26
53	AMP-Activated Protein (AMPK) in Pathophysiology of Pregnancy Complications. International Journal of Molecular Sciences, 2018, 19, 3076.	1.8	26
54	Cancer biology in diabetes. Journal of Diabetes Investigation, 2014, 5, 251-264.	1.1	25

#	Article	IF	CITATIONS
55	Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice. Scientific Reports, 2019, 9, 7519.	1.6	25
56	Loss of Mitochondrial Control Impacts Renal Health. Frontiers in Pharmacology, 2020, 11, 543973.	1.6	25
57	Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis and Tissue Repair, 2011, 4, 25.	3.4	23
58	A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity. Nutrition and Metabolism, 2018, 15, 20.	1.3	23
59	Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling. Molecular Cancer Research, 2021, 19, 61-73.	1.5	22
60	The Relevance of the Renin-Angiotensin System in the Development of Drugs to Combat Preeclampsia. International Journal of Endocrinology, 2015, 2015, 1-12.	0.6	21
61	N-Acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators. Biochemical and Biophysical Research Communications, 2006, 342, 758-765.	1.0	20
62	CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology. Cancers, 2021, 13, 2191.	1.7	20
63	Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 6027.	1.8	19
64	Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 805.	1.8	18
65	A ketogenic amino acid rich diet benefits mitochondrial homeostasis by altering the AKT/4EBP1 and autophagy signaling pathways in the gastrocnemius and soleus. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1547-1555.	1.1	17
66	Dipeptidyl peptidase-4 inhibition and renoprotection. Current Opinion in Nephrology and Hypertension, 2017, 26, 56-66.	1.0	16
67	Sodium–glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells. Diabetes and Metabolism, 2020, 46, 353-361.	1.4	16
68	FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p. Biochemical and Biophysical Research Communications, 2018, 495, 2214-2220.	1.0	13
69	<i>N</i> â€acetylâ€serylâ€aspartylâ€lysylâ€proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects. Journal of Diabetes Investigation, 2020, 11, 516-526.	1.1	13
70	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. Diabetology International, 2021, 12, 87-100.	0.7	12
71	Combat Diabetic Nephropathy: From Pathogenesis to Treatment. Journal of Diabetes Research, 2014, 2014, 1-2.	1.0	11
72	The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clinical and Experimental Nephrology, 2015, 19, 65-74.	0.7	11

#	Article	IF	CITATIONS
73	Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon. Frontiers in Pharmacology, 2019, 10, 476.	1.6	11
74	The impact of micronutrient deficiency on pregnancy complications and development origin of health and disease. Journal of Obstetrics and Gynaecology Research, 2021, 47, 1965-1972.	0.6	9
75	Three ileus cases associated with the use of dipeptidyl peptidaseâ€4 inhibitors in diabetic patients. Journal of Diabetes Investigation, 2013, 4, 673-675.	1.1	8
76	The pathological significance of dipeptidyl peptidase-4 in endothelial cell homeostasis and kidney fibrosis. Diabetology International, 2016, 7, 212-220.	0.7	7
77	Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Research and Care, 2017, 5, e000391.	1.2	7
78	Effect of switching to teneligliptin from other dipeptidyl peptidaseâ€4 inhibitors on glucose control and renoprotection in typeA2 diabetes patients with diabetic kidney disease. Journal of Diabetes Investigation, 2019, 10, 706-713.	1.1	7
79	βklotho is essential for the antiâ€endothelial mesenchymal transition effects of <i>N</i> â€acetylâ€serylâ€aspartylâ€lysylâ€proline. FEBS Open Bio, 2019, 9, 1029-1038.	1.0	7
80	Cyclic and intermittent very lowâ€protein diet can have beneficial effects against advanced diabetic nephropathy in Wistar fatty (<i>fa/fa</i>) rats, an animal model of type 2 diabetes and obesity. Nephrology, 2017, 22, 1030-1034.	0.7	5
81	N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30Âml/min/1.73Âm2. Clinical and Experimental Nephrology, 2019, 23,	1834-101	2 ⁵ .
82	CDâ€1 <i>^{db/db}</i> mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis. Journal of Diabetes Investigation, 2020, 11, 1470-1481.	1.1	5
83	STOX1 deficiency is associated with renin-mediated gestational hypertension and placental defects. JCI Insight, 2021, 6, .	2.3	4
84	Editorial: Combating Diabetes and Diabetic Kidney Disease. Frontiers in Pharmacology, 2021, 12, 716029.	1.6	4
85	Dietary Magnesium Insufficiency Induces Salt-Sensitive Hypertension in Mice Associated With Reduced Kidney Catechol-O-Methyl Transferase Activity. Hypertension, 2021, 78, 138-150.	1.3	4
86	Thyroid crisis caused by metastatic thyroid cancer: an autopsy case report. BMC Endocrine Disorders, 2021, 21, 213.	0.9	3
87	Combating Kidney Fibrosis. BioMed Research International, 2014, 2014, 1-2.	0.9	2
88	Glucose Intolerance and Insulin Resistance: Relevance in Preeclampsia. Comprehensive Gynecology and Obstetrics, 2018, , 85-98.	0.0	2
89	Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opinion on Drug Safety, 2022, 21, 425-434.	1.0	2
90	Analysis of eGFR index category and annual eGFR slope association with adverse clinical outcomes using real-world Japanese data: a retrospective database study. BMJ Open, 2022, 12, e052246.	0.8	2

#	Article	IF	CITATIONS
91	Editorial: Receptor Biology and Cell Signaling in Diabetes. Frontiers in Pharmacology, 2022, 13, 864117.	1.6	2
92	Angiogenic defects in preeclampsia: What is known, and how are such defects relevant to preeclampsia pathogenesis?. Hypertension Research in Pregnancy, 2013, 1, 57-65.	0.1	1
93	Adenosine/A1R signaling pathway did not play dominant roles on the influence of SGLT2 inhibitor in the kidney of BSAâ€overloaded STZâ€induced diabetic mice. Journal of Diabetes Investigation, 2022, , .	1.1	1
94	Concerted efforts to combat diabetic complications. Kidney International, 2016, 89, 269-271.	2.6	0
95	Severe electrolytes disorders with the interstitial kidney alterations in the patient with the history of total thyroidectomy and parathyroidectomy: possible role of vitamin D deficiency. Clinical Case Reports (discontinued), 2018, 6, 983-989.	0.2	Ο
96	Classical molecule in diabetic kidney hypertrophy is linked to defects in selfâ€eating through fineâ€ŧuning. Journal of Diabetes Investigation, 2021, 12, 686-688.	1.1	0
97	Osteomalacia caused by atypical renal tubular acidosis with vitamin D deficiency: a case report. CEN Case Reports, 2021, 10, 294-300.	0.5	Ο
98	Conditional deletion of β1â€integrin from urothelium results in bladder dysfunction and abnormal voiding. FASEB Journal, 2012, 26, .	0.2	0